| 摘要: |
| 摘 要：目的 探讨节拍化疗在卡培他滨+奥沙利铂+贝伐珠单抗治疗晚期结肠癌中的运用价值。方法 将 92 例
晚期结肠癌患者随机分为观察组和对照组，每组 46 例。对照组采用传统给药方法的卡培他滨+奥沙利铂+贝伐珠单抗治
疗，观察组采用卡培他滨节拍化疗+奥沙利铂+贝伐珠单抗治疗，疗程 21 d。对比两组的近期疗效、不良反应、免疫功能指
标、血清肿瘤标志物和生活质量。结果 两组近期疗效差异无统计学意义（P>0.05）。观察组白细胞降低、胃肠道反应、血
小板降低、手足综合征的程度均明显轻于对照组（P<0.05）。观察组治疗后的CD3+、CD4+、CD4+/CD8+、NK均明显高于对
照组（P<0.01 或 0.05）。观察组治疗后的CEA、CA19-9 和CCSA-1 均明显低于对照组（P<0.05）。与对照组相比，观察组
治疗后的功能领域评分明显高，症状领域评分明显低（P<0.05）。结论 节拍化疗应用于卡培他滨+奥沙利铂+贝伐珠单
抗中治疗晚期结肠癌可降低不良反应发生率和血清肿瘤标志物水平，减轻免疫功能的损伤，提高患者的生活质量。 |
| 关键词: 节拍化疗 卡培他滨 奥沙利铂 贝伐珠单抗 晚期结肠癌 |
| DOI： |
|
| 基金项目:湛江市科技计划项目（2022B01204） |
|
| The application study of metronomic chemotherap in the treatment of advanced colon cancer with capecitabine, oxaliplatin, and bevacizumab |
|
| () |
| Abstract: |
| Abstract: Objective To investigate the metronomic chemotherap in the treatment of advanced colon cancer with
capecitabine, oxaliplatin, and bevacizumab. Methods A total of 92 patients with advanced colon cancer were randomly
divided into an observation group and a control group, with 46 cases in each group. The control group was treated with
traditional administration methods of capecitabine, oxaliplatin, and bevacizumab. The observation group was treated with
metronomic chemotherap with capecitabine , oxaliplatin, and bevacizumab. The efficacy, adverse reactions, immune function
indicators, serum tumor markers, and quality of life between the two groups were compared. Results There was no significant
difference in the short-term efficacy between the two groups (P>0.05). The degree of leukopenia, gastrointestinal reactions,
thrombocytopenia, and hand foot syndrome in the observation group was significantly lighter than those in the control group
(P<0.05). After treatment, the CD3+, CD4+, CD4+/CD8+, and NK levels in the observation group were significantly higher than
those in the control group (P<0.05 or 0.01). The CEA, CA19-9, and CCSA-1 levels in the observation group after treatment
were significantly lower than those in the control group (P<0.05). The observation group showed significantly higher scores
in functional areas and lower scores in symptom areas after treatment compared with the control group (P<0.05). Conclusion
Advanced colon cancer could reduce the incidence of adverse reactions and serum tumor marker concentrations, alleviate
immune function damage, and improve patients’quality of life when treated with metronomic chemotherap with capecitabine,
oxaliplatin, and bevacizumab, suggesting metronomic chemotherapy is a promising way to target the cancers |
| Key words: metronomic chemotherap capecitabine oxaliplatin bevaczumab advanced colon cancer |